Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

Lagging acceptance of generic and biosimilar drug products; the rest of the story / Professor Philip D Walson, MD, USA


Response to the Opinion entitled ‘Biosimilars drug development: time for a paradigm shift?’ / Robin Thorpe, PhD, FRCPath, UK

Original Research

Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars / Michael S Reilly, Esq, USA; Jane Barratt, PhD, Canada

Pharmacokinetic bioequivalence of sitagliptin phosphate tablet formulations: a randomized, open-label, crossover study in healthy volunteers / Chuei Wuei Leong, PhD; Elton Sagim, BBiomedSc; Kar Ming Yee, BPharm; Muhammad Shalhadi Saharuddin, BSc; Nik Mohd Zulhakimi Nik Abdullah, BSc; Noramirah Farhanah Saberi, BSc; Rajavikraman Boopathy, DipSc; Shahnun Ahmad, MBBS; Atiqah Amran, BSc; Raman Batheja, PhD; Rajan Sharma, MBBS; Kiran Kumar Vuppalavanchu, MPharm, Malaysia

Pharmacokinetics and relative bioavailability of sitagliptin hydrochloride and sitagliptin phosphate tablets formulations: a randomized, open-label, crossover study in healthy male volunteers / Chuei Wuei Leong, PhD; Elton Sagim, BBiomedSc, Kar Ming Yee, BPharm; Muhammad Shalhadi Saharuddin, BSc; Sharifah Radziah Syed Abd Rahim, MSc; Khairil Sabri, BSc; Mohd Zulhairi Jamaluddin, BSc; Shahnun Ahmad, MBBS; Atiqah Amran1, BSc; Rabab F Tayyem, PhD, Malaysia

Review Articles

Statistical tests for detecting reference product change in biosimilar studies / Jiayin Zheng1, PhD; Peijin Wang2, MS; Yixin Wang3, PhD; Shein-Chung Chow2, PhD, USA


Biosimilars drug development: time for a paradigm shift? / Sandeep N Athalye, MS; Shivani Mittra, MPharm, PhD; Ankitkumar M Ranpura, MD, India

Meeting Report

Non-medical switching of biologicals/biosimilars Canada, Europe and the US: a webinar report / Michael S Reilly, Esq; Gail Attara; Ralph D McKibbin, MD, FACP, FACG, AGAF; Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP, USA/Canada


Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD, Iran

Pharma News

Biosimilars approved in Brazil 2022 / Sílvia Helena Cestari de Oliveira, MSc, Brazil

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Source URL:

Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048